. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology. 2003 Jan 28;60(2):253-60. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.